Research Analysts Set Expectations for Biodesix Q1 Earnings

Biodesix, Inc. (NASDAQ:BDSX) – Equities researchers at William Blair issued their Q1 2026 earnings estimates for Biodesix in a research report issued to clients and investors on Tuesday, March 4th. William Blair analyst A. Brackmann forecasts that the company will post earnings of ($0.05) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Biodesix’s current full-year earnings is ($0.35) per share. William Blair also issued estimates for Biodesix’s Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.14) EPS.

Biodesix (NASDAQ:BDSX) last released its earnings results on Monday, March 3rd. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. The business had revenue of $20.43 million for the quarter, compared to the consensus estimate of $19.92 million. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%.

Biodesix Price Performance

NASDAQ BDSX opened at $0.72 on Wednesday. Biodesix has a 1 year low of $0.64 and a 1 year high of $2.04. The business’s fifty day moving average is $1.11 and its two-hundred day moving average is $1.41. The stock has a market capitalization of $104.74 million, a P/E ratio of -1.85 and a beta of 1.06. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40.

Insider Buying and Selling

In related news, CEO Scott Hutton sold 83,660 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total value of $76,967.20. Following the completion of the transaction, the chief executive officer now owns 701,947 shares in the company, valued at $645,791.24. This trade represents a 10.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 128,702 shares of company stock worth $118,406 in the last three months. 69.20% of the stock is currently owned by insiders.

Institutional Trading of Biodesix

Institutional investors and hedge funds have recently bought and sold shares of the stock. Balyasny Asset Management L.P. acquired a new position in shares of Biodesix in the fourth quarter worth about $29,000. Barclays PLC boosted its stake in Biodesix by 1,140.5% in the 3rd quarter. Barclays PLC now owns 23,036 shares of the company’s stock worth $41,000 after purchasing an additional 21,179 shares during the period. Boothbay Fund Management LLC purchased a new position in Biodesix during the 4th quarter worth approximately $52,000. MYDA Advisors LLC acquired a new stake in Biodesix during the 4th quarter valued at $76,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Biodesix by 385.9% in the fourth quarter. Cubist Systematic Strategies LLC now owns 51,024 shares of the company’s stock valued at $78,000 after purchasing an additional 40,524 shares in the last quarter. Institutional investors and hedge funds own 20.96% of the company’s stock.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.